Universe Ebit vs Net Income Analysis
| UPC Stock | USD 1.16 0.22 15.94% |
Universe Pharmaceuticals financial indicator trend analysis is much more than just breaking down Universe Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Universe Pharmaceuticals is a good investment. Please check the relationship between Universe Pharmaceuticals Ebit and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.
Ebit vs Net Income
Ebit vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Universe Pharmaceuticals Ebit account and Net Income. At this time, the significance of the direction appears to have totally related.
The correlation between Universe Pharmaceuticals' Ebit and Net Income is 1.0. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Net Income in the same time period over historical financial statements of Universe Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Universe Pharmaceuticals' Ebit and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Universe Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Ebit i.e., Universe Pharmaceuticals' Ebit and Net Income go up and down completely randomly.
Correlation Coefficient | 1.0 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Ebit
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Universe Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Universe Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Universe Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Universe Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.As of December 11, 2024, Tax Provision is expected to decline to about 1.6 M. In addition to that, Selling General Administrative is expected to decline to about 1.8 M
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 162.4K | 156.8K | 180.3K | 153.8K | Depreciation And Amortization | 533.9K | 508.8K | 457.9K | 413.1K |
Universe Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Universe Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Universe Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 28.8M | 70.1M | 59.5M | 53.3M | 61.3M | 47.2M | |
| Short Long Term Debt Total | 2.6M | 4.3M | 3.9M | 5.5M | 6.3M | 3.9M | |
| Other Current Liab | 1.3M | 464.0K | 5.9M | 3.3M | 2.9M | 3.2M | |
| Total Current Liabilities | 8.0M | 11.2M | 13.1M | 13.8M | 15.8M | 12.8M | |
| Total Stockholder Equity | 20.8M | 58.9M | 46.4M | 39.5M | 45.5M | 34.4M | |
| Net Tangible Assets | 12.2M | 20.6M | 58.8M | 46.3M | 53.2M | 32.4M | |
| Property Plant And Equipment Net | 4.4M | 15.4M | 13.6M | 15.0M | 17.2M | 10.6M | |
| Net Debt | (7.4M) | (3.7M) | (1.8M) | 197.2K | 226.8K | 238.1K | |
| Retained Earnings | 13.7M | 25.1M | 16.3M | 10.2M | 11.7M | 13.6M | |
| Accounts Payable | 2.7M | 5.3M | 3.1M | 4.6M | 5.3M | 3.8M | |
| Cash | 10.1M | 8.1M | 5.7M | 5.3M | 6.1M | 7.1M | |
| Non Current Assets Total | 5.5M | 19.7M | 18.0M | 16.5M | 18.9M | 13.1M | |
| Other Assets | 168.1K | 186.5K | 14.1M | 12.9M | 14.9M | 15.6M | |
| Cash And Short Term Investments | 10.1M | 21.8M | 18.9M | 18.5M | 21.3M | 14.4M | |
| Net Receivables | 10.9M | 15.8M | 15.2M | 10.7M | 12.3M | 12.2M | |
| Liabilities And Stockholders Equity | 28.8M | 70.1M | 59.5M | 53.3M | 61.3M | 47.2M | |
| Inventory | 1.9M | 2.5M | 2.2M | 3.3M | 3.0M | 2.8M | |
| Other Current Assets | 443.7K | 10.4M | 5.3M | 4.2M | 4.9M | 3.7M | |
| Total Liab | 8.0M | 11.2M | 13.1M | 13.8M | 15.8M | 12.8M | |
| Net Invested Capital | 23.4M | 63.3M | 50.4M | 45.0M | 51.8M | 38.4M | |
| Long Term Investments | 735K | 744.9K | 702.9K | 685.3K | 616.8K | 572.9K | |
| Property Plant And Equipment Gross | 4.4M | 15.4M | 19.3M | 21.0M | 24.2M | 12.8M | |
| Short Long Term Debt | 2.6M | 4.3M | 3.9M | 5.5M | 6.3M | 3.9M | |
| Total Current Assets | 23.3M | 50.5M | 41.5M | 36.8M | 42.3M | 34.1M | |
| Accumulated Other Comprehensive Income | 3.3M | 4.5M | 772.8K | 26.3K | 23.6K | 22.5K | |
| Net Working Capital | 15.3M | 39.3M | 28.4M | 23.1M | 26.5M | 21.3M | |
| Short Term Debt | 2.6M | 4.3M | 3.9M | 5.5M | 6.3M | 3.9M | |
| Intangible Assets | 174.8K | 178.5K | 157.5K | 148.6K | 133.7K | 135.3K | |
| Property Plant Equipment | 4.6M | 4.4M | 4.7M | 4.3M | 3.8M | 3.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Universe Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Universe Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.82) | Earnings Share (76.35) | Revenue Per Share 7.351 | Quarterly Revenue Growth (0.30) | Return On Assets (0.06) |
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Universe Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.